Companies
Sanofi
French pharma leader — Dupixent biologic blockbuster and Warp Speed vaccine contributor; major biologics manufacturing footprint across France, Germany, and US.
- Country
- France
- Revenue
- €41.6B
- Employees
- ~90,000 emp
GMP EU
FDA GMP
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| genome-engineering | ✓ | ✓ | — | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaepamoa-chinaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Sanofi intends to invest at least $20 billion in the US through 2030. (2025-05-14) | prnewswire.com |
| Production site | Sanofi operates 7 specialty care sites, 10 vaccine sites, and 23 general medicines sites globally. (2025-03-20) | bioprocessintl.com |
| Capacity | Global manufacturing network produces 2 billion doses annually; US operations deliver over 600 million units annually. (2026-08-31) | sanofi.com · sanofi.us |
| Certification | The Neuville-sur-Saône facility is designed to meet LEED certification standards. (2024-05-13) | sanofi.com |
| Regulatory approval | Sanofi received ten regulatory approvals across immunology, rare diseases, and other areas in 2025. (2025-12-31) | sec.gov |
Independent sources: bioprocessintl.com · prnewswire.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
| Xenobiology & expanded genetic alphabet (XNA) | genome-engineering | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.